Lupus & antiphospholipid syndrome
Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China
Main finding · Extra-criteria manifestations (multivariable analysis)Result — go to the resultOdds ratio 2.94 95% CI 1.29–6.70Authors' conclusion
Anti-β2GPI-DI IgG was associated with extra-criteria manifestations in patients with APS.
Study context
- Population
- Patients with antiphospholipid syndrome (APS) (primary or secondary to SLE) and SLE without APS, China169 with APS
- Participants
- 378 patients
- Exposure
- Anti-β2GPI-DI IgG positive vs negative
- Primary APSn = 119
- SAPSn = 50
- SLEn = 209reference
- Outcome
- Association of serum anti-β2GPI-DI IgG with extra-criteria manifestations (thrombocytopenia, autoimmune haemolytic anaemia, valvular lesions, APS nephropathy, non-vascular neurological manifestations)
Methodological detailsmultivariable analysis, Serum anti-β2GPI-DI IgG measured by chemiluminescent immunoassay
- Multivariable analysis
- Serum anti-β2GPI-DI IgG measured by chemiluminescent immunoassay
Main finding
As reported in the abstract
Extra-criteria manifestations (multivariable analysis)
Odds ratio
2.94
95% CI 1.29–6.70
Anti-β2GPI-DI IgG positivevs negative
OR 2.94 (95% CI 1.29–6.70)
- Higher anti-β2GPI-DI IgG positivity in patients with extra-criteria manifestations
- P = 0.001
- Higher anti-β2GPI-DI IgG titres in patients with extra-criteria manifestations
- P < 0.001
Observational data: associations, not effects.
Further findings
- Diagnosis of SAPS among patients with SLE — SLE
- 8.1%
- Diagnosis of SAPS among patients with SLE — Specificity of anti-β2GPI-DI for SAPS among SLE
- 91.9%
- Diagnosis of SAPS among patients with SLE: 8.1% = anti-β2GPI-DI positivity in SLE controls
Anti-β2GPI-DI IgG positivity in APS
- Positive for anti-β2GPI-DI IgG among 169 APS patients
- 55 (32.5%)
- Share of anti-β2GPI IgG positive patients
- 77.5%
- Anti-β2GPI-DI IgG positive with triple aPL positivity
- 96.4%
Association with thrombosis and pregnancy morbidity
- Recurrent thrombosis before APS diagnosis
- P = 0.015
- Microvascular thrombosis
- P = 0.038
- Not associated with pregnancy morbidity
Follow-up events · median follow-up of 25 months
- Anti-β2GPI-DI IgG positive patients showed a tendency of more extra-criteria events, but not thrombotic events
Original publication
Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China. Lupus Sci Med. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →